Investigation of the Effectiveness of Tocilizumab on COVID-19 Patients: A Retrospective Study
| Author | Behnaz Khodabakhshi | en |
| Author | Romina Masoumifar | en |
| Author | Mahdi Mazandarani | en |
| Author | Narges Lashkarbolouk | en |
| Author | Gholamreza Roshandel | en |
| Orcid | Behnaz Khodabakhshi [0000-0003-0456-9192] | en |
| Orcid | Mahdi Mazandarani [0000-0001-8972-6171] | en |
| Orcid | Narges Lashkarbolouk [0000-0001-9443-3453] | en |
| Orcid | Gholamreza Roshandel [0000-0002-5494-0722] | en |
| Issued Date | 2024-01-31 | en |
| Abstract | Background: Tocilizumab (TCZ), an interleukin-6 receptor inhibitor, has been considered a potential treatment for severe COVID-19 cases. However, data on its effectiveness remain limited. Objectives: This study aims to evaluate the outcomes of using TCZ in patients with severe COVID-19 during the fifth wave of the pandemic. Methods: This retrospective cohort study was conducted on 114 patients with severe COVID-19 who were hospitalized in the ICU at Sayyad Shirazi Hospital in Gorgan, Iran, during the fifth wave. The patients were divided into two groups: 57 received TCZ along with standard treatment (remdesivir and corticosteroids), while 57 received only standard treatments. Results: The mean age of the participants was 53.02 ± 17.29 years, with 54.4% being female. The mean length of hospitalization was 20.16 ± 17.30 days. Statistical analysis showed no significant differences regarding age (P = 0.34), gender (P = 0.25), or length of hospitalization (P = 0.84). Additionally, 43.9% of the participants had underlying health conditions, with no significant difference in their distribution (P = 0.70). The intubation rate was 3.5% in the TCZ group compared to 5.3% in the control group, with no significant association between the two groups (P = 0.64). Mortality rates were 47.4% (27 patients) in the TCZ group and 56.1% (32 patients) in the control group, with statistical analysis revealing no significant difference between the two groups (P = 0.34). However, in patients aged 60 years and older, the mortality rate was significantly higher in the control group than in the TCZ group (P = 0.03). Conclusion: The use of TCZ in severe COVID-19 patients hospitalized in the ICU was associated with a reduced mortality risk among patients aged 60 years and older. | en |
| DOI | https://doi.org/10.5812/chbs-151051 | en |
| Keyword | Tocilizumab | en |
| Keyword | COVID-19 | en |
| Keyword | Mortality | en |
| Keyword | Interleukin-6 Family | en |
| Publisher | Brieflands | en |
| Title | Investigation of the Effectiveness of Tocilizumab on COVID-19 Patients: A Retrospective Study | en |
| Type | Research Article | en |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- chbs-2-3-151051-publish-pdf.pdf
- Size:
- 358.13 KB
- Format:
- Adobe Portable Document Format
- Description:
- Article/s PDF